Author:
Vidovic Dejan,Huynh Thomas T.,Konda Prathyusha,Dean Cheryl,Cruickshank Brianne M.,Sultan Mohammad,Coyle Krysta M.,Gujar Shashi,Marcato Paola
Funder
Gouvernement du Canada | Canadian Institutes of Health Research
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Molecular Biology
Reference71 articles.
1. Peddi PF, Ellis MJ, Ma C. Molecular basis of triple negative breast cancer and implications for therapy. IntJ Breast Cancer. 2012;2012:217185.
2. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11:259–73.
3. Li H, Ma F, Wang H, Lin C, Fan Y, Zhang X, et al. Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer. Int J Biol Markers. 2013;28:357–64.
4. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44 + /CD24− phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients. Med Oncol. 2011;28:745–52.
5. Wu Y, Sarkissyan M, Elshimali Y, Vadgama JV. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44 + , Low in CD24 + , and have loss of PTEN. PLoS One. 2013;8:1–12.
Cited by
89 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献